{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:39:44Z","timestamp":1793338784203,"version":"4.5.0"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[1996,6,1]],"date-time":"1996-06-01T00:00:00Z","timestamp":833587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Infect Immun"],"published-print":{"date-parts":[[1996,6]]},"abstract":"<jats:p>As a first step in formulating an improved plague vaccine, we developed a simple purification strategy that produced high yields of pure cell-associated and culture supernatant-derived fraction 1 capsular antigen (F1) from both avirulent Yersinia pestis C092 (Pgm- Lcr-) and an Escherichia coli F1-producing recombinant strain. Cell-associated F1 was partially purified by sequential ammonium sulfate precipitations of a sodium chloride extract of acetone-dried bacteria harvested from broth cultures. Cell-free F1 was precipitated directly from culture supernatants with a single application of 30% ammonium sulfate. By exploiting the aggregative property of F1, large quantities of purified high-molecular-weight F1 species from both cell extracts and supernatants were isolated in the void volume of a preparative gel filtration column. Highly purified, endotoxin-free F1, combined with two different adjuvants, induced very high F1 titers in mice and protected them against either subcutaneous (70 to 100% survival) or aerosol (65 to 84% survival) challenge with virulent organisms. This protection was independent of the source of the antigen and the adjuvant used. F1-induced protection against both subcutaneous and aerosol challenge was also significantly better than that conferred by immunization with the licensed killed whole-cell vaccine. Our results indicate that F1 antigen represents a major protective component of previously studied crude capsule preparations, and immunity to F1 antigen provides a primary means for the host to overcome plague infection by either the subcutaneous or respiratory route.<\/jats:p>","DOI":"10.1128\/iai.64.6.2180-2187.1996","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T18:59:15Z","timestamp":1578337155000},"page":"2180-2187","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":158,"title":["Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge"],"prefix":"10.1128","volume":"64","author":[{"given":"G P","family":"Andrews","sequence":"first","affiliation":[{"name":"Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D G","family":"Heath","sequence":"additional","affiliation":[{"name":"Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"G W","family":"Anderson","sequence":"additional","affiliation":[{"name":"Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S L","family":"Welkos","sequence":"additional","affiliation":[{"name":"Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Friedlander","sequence":"additional","affiliation":[{"name":"Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","container-title":["Infection and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/iai.64.6.2180-2187.1996","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/iai.64.6.2180-2187.1996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T08:47:52Z","timestamp":1646470072000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/iai.64.6.2180-2187.1996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,6]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1996,6]]}},"alternative-id":["10.1128\/iai.64.6.2180-2187.1996"],"URL":"https:\/\/doi.org\/10.1128\/iai.64.6.2180-2187.1996","relation":{},"ISSN":["0019-9567","1098-5522"],"issn-type":[{"value":"0019-9567","type":"print"},{"value":"1098-5522","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,6]]},"assertion":[{"value":"1996-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}